T-Cell Responses in Children to Internal Influenza Antigens, 1 Year After Immunization with Pandemic H1N1 Influenza Vaccine, and Response to Revaccination with Seasonal Trivalent-inactivated Influenza Vaccine

Pediatric Infectious Disease Journal

Volumn 31, Issue 6, 2012, Pages e86-e91

  Lambe, Teresa ^a   Spencer, Alexandra J ^a   Mullarkey, Caitlin E ^a   Antrobus, Richard D ^a   Yu, Ly Mee ^a   de Whalley, Philip ^a   Thompson, Ben A V ^a   Jones, Claire ^a   Chalk, Jem ^a   Kerridge, Simon ^a   Hill, Adrian V S ^a   Snape, Matthew D ^a   Pollard, Andrew J ^a   Gilbert, Sarah C ^a  

^a NIHR Biomedical Researcg Centre   (United Kingdom)

Author keywords

Pandemic H1N1 vaccine; Pediatric; T cell responses; Trivalent influenza vaccine

Indexed keywords

ANTIGEN; GAMMA INTERFERON; HEMAGGLUTININ; INFLUENZA VACCINE; MATRIX PROTEIN 1; NONSTRUCTURAL PROTEIN 1; NUCLEOPROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; HUMAN; IMMUNOGENICITY; INFANT; INFLUENZA A (H1N1); INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVACCINATION; REVIEW; SCHOOL CHILD; SEASONAL VARIATION; T LYMPHOCYTE; TREATMENT RESPONSE; VIRION;

ANTIGENS, VIRAL; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MALE; VACCINES, INACTIVATED;

EID: 84861527368     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318255e443     Document Type: Article

References (30)

1. Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25:5086-5096
2. Bautista E, Chotpitayasunondh T, Gao Z, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010;362:1708-1719
3. Nguyen-Van-Tam JS, Openshaw PJ, Hashim A, et al. Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). Thorax. 2010;65:645-651
4. Poehling KA, Edwards KM, Weinberg GA, et al. The underrecognized burden of influenza in young children. N Engl J Med. 2006;355:31-40
5. Scheifele DW, Ward BJ, Dionne M, et al. Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children. Pediatr Infect Dis J. 2011;30:402-407
6. Nicholson KG, Abrams KR, Batham S, et al. A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart. Health Technol Assess. 2010;14:193-334
7. Waddington C, Andrews N, Hoschler K, et al. Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age. Health Technol Assess. 2010;14:1-130
8. Roman F, Vaman T, Gerlach B, et al. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine. 2010;28:1740-1745
9. Cheong HJ, Song JY, Heo JY, et al. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine. Clin Vaccine Immunol. 2011;18:1358-1364
10. Waddington CS, Walker WT, Oeser C, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ. 2010;340:c2649
11. Walker WT, de Whalley P, Andrews N, et al. H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on study. Clin Infect Dis. 2012;54:661-669
12. Terajima M, Cruz J, Leporati AM, et al. Influenza A virus matrix protein 1-specific human CD8+ T-cell response induced in trivalent inactivated vaccine recipients. J Virol. 2008;82:9283-9287
13. Rastogi D, Wang C, Mao X, et al. Antigen-specific immune responses to influenza vaccine in utero. J Clin Invest. 2007;117:1637-1646
14. McMichael AJ, Gotch FM, Noble GR, et al. Cytotoxic T-cell immunity to influenza. N Engl J Med. 1983;309:13-17
15. Benton KA, Misplon JA, Lo CY, et al. Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells. J Immunol. 2001;166:7437-7445
16. Berthoud TK, Hamill M, Lillie PJ, et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. CID. 2011;52:1-7
17. Lee LY, Ha do LA, Simmons C, et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest. 2008;118:3478-3490
18. Goodman AG, Heinen PP, Guerra S, et al. A human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virus. PLoS ONE. 2011;6:e25938
19. Atmar RL, Keitel WA. Adjuvants for pandemic influenza vaccines. Curr Top Microbiol Immunol. 2009;333:323-344
20. Khurana S, Verma N, Yewdell JW, et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med. 2011;3:85ra48
21. Durando P, Iudici R, Alicino C, et al. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. Human Vaccines. 2011;7(Suppl):29-40
22. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2008 CD004879
23. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol. 2011;12:509-517
24. Wrammert J, Koutsonanos D, Li GM, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med. 2011;208:181-193
25. Epstein SL, Kong WP, Misplon JA, et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine. 2005;23:5404-5410
26. McElhaney JE, Xie D, Hager WD, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol. 2006;176:6333-6339
27. Donnelly JJ, Friedman A, Ulmer JB, et al. Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination. Vaccine. 1997;15:865-868
28. Laddy DJ, Yan J, Khan AS, et al. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol. 2009;83:4624-4630
29. Breathnach CC, Clark HJ, Clark RC, et al. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge. Vaccine. 2006;24:1180-1190
30. Remarque EJ, Nijhuis EW, Hinloopen B, et al. Correlation between the antibody response to influenza vaccine and helper T cell subsets in healthy aging. Vaccine. 1996;14:127-130